Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
暂无分享,去创建一个
P. V. van Riel | F. V. D. van den Hoogen | A. D. den Broeder | B. V. D. van den Bemt | G. Wolbink | Y. Hekster | G. Snijders | B. Benraad
[1] Issa J Dahabreh,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. , 2008, Clinical therapeutics.
[2] Y. Goekoop-Ruiterman,et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[3] Mahboob Rahman,et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[4] P. V. van Riel,et al. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. , 2007, Rheumatology.
[5] K. Bendtzen,et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.
[6] J. Siegel,et al. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. , 2006, JAMA.
[7] H. H. Kuper,et al. The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice , 2006 .
[8] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[9] B. Dijkmans,et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[10] B. Haraoui,et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. , 2006, The Journal of rheumatology.
[11] M. Malaise,et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. , 2005, Rheumatology.
[12] I. Nestorov. Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.
[13] B. Dijkmans,et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[14] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[15] L. Klareskog,et al. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect , 2004, Annals of the rheumatic diseases.
[16] D. Boumpas,et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit , 2004, Annals of the rheumatic diseases.
[17] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[18] P. V. van Riel,et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. , 2002, Rheumatology.
[19] E. Keystone,et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.
[20] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[21] A. Markham,et al. Infliximab: a review of its use in the management of rheumatoid arthritis. , 2000, Drugs.
[22] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[23] P. van Riel,et al. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.
[24] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.